Tracking cholinergic pathways from psychological and chemical stressors to variable neurodeterioration paradigms

Current Opinion in Neurology

Volumn 12, Issue 6, 1999, Pages 739-743

  Kaufer, Daniela ^a   Soreq, Hermona ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR;

ALZHEIMER DISEASE; CHOLINERGIC SYSTEM; HUMAN; MENTAL STRESS; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; REVIEW; RISK FACTOR;

BRAIN; CHOLINERGIC FIBERS; HUMANS; NEURAL PATHWAYS; NEURODEGENERATIVE DISEASES; OXIDATIVE STRESS; STRESS, PSYCHOLOGICAL;

EID: 0033402485     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199912000-00014     Document Type: Review

References (53)

1. McEwen BS. Stress, adaptation, and disease. Allostasis and altostatic load. Ann N Y Acad Sci 1998; 840:33-44. This is a thorough review of the hormonal contributions towards stress effects.
2. Sapolsky RM. Stress, glucocorticoids, and damage to the nervous system: the current state of confusion. Stress 1996; 1:1-19.
3. Kaufer D, Friedman A, Seidman S, Soreq H. Acute stress facilitates long-lasting changes in cholinergic gene expression. Nature 1998; 393:373-377.
4. Morrow BA, Elsworth JD, Inglis FM, Roth RH. An antisense oligonucleotide reverses the footshock-induced expression of fos in the rat medial prefrontai cortex and the subsequent expression of conditioned fear-induced immobility. J Neurosci 1999; 19:5666-5673.
5. Jolly-Tornetta C, Gao ZY, Lee VM, Wolf BA. Regulation of amyloid precursor protein secretion by glutamate receptors in human Ntera 2 neurons. J Biol Chem 1998; 273:14015-14021.
6. Nitsch RM, Deng A, Wurtman RJ, Growdon JH. Metabotropic glutamate receptor subtype mGluR1 alpha stimulates the secretion of the amyloid beta-protein precursor ectodomain. J Neurochem 1997; 69:704-712.
7. Willard LB, Hauss-Wegrzyniak B, Wenk GL. Pathological and biochemical consequences of acute and chronic neuroinflammation within the basal forebrain cholinergic system of rats. Neuroscience 1999; 88:193-200.
8. Schneider H, Pitossi F, Balschun D, Wagner A, del Rey A, Besedovsky HO. A neuromodulatory role of interleukin-1beta in the hippocampus. Proc Natl Acad Sci USA 1998; 95:7778-7783.
9. Murray CA, Lynch MA. Evidence that increased hippocampal expression of the cytokine interleukin-1 beta is a common trigger for age- and stress-induced impairments in long-term potentiation. J Neurosci 1998; 18:2974-2981. This interesting paper highlights the importance of glia-neuronal interactions in stress responses.
10. Coyle JT, Price DL, DeLong MR. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 1983; 219:1184-1190.
11. Mesulam MM. Alzheimer plaques and cortical cholinergic innervation. Neuroscience 1986; 17:275-276.
12. Alvarez A, Opazo C, Alarcon R, Garrido J, Inestrosa NC. Acetylcholinesterase promotes the aggregation of amyloid-beta-peptide fragments by forming a complex with the growing fibrils. J Mol Biol 1997; 272:348-361.
13. Inestrosa NC, Alvarez A, Perez CA, Moreno RD, Vicente M, Linker C, et al. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron 1996; 16:881-891.
14. Sberna G, Saez-Valero J, Li QX, Czech C, Beyreuther K, Masters CL, et al. Acetylcholinesterase is increased in the brains of transgenic mice expressing the C-terminal fragment (CT100) of the beta-amyloid protein precursor of Alzheimer's disease. J Neurochem 1998; 71:723-731. This transgenic study unravels an important connection between AChE and β-amyloid accumulation.
15. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400:173-177. A pioneering demonstration of prophylactic and therapeutic prevention of plaque formation is provided.
16. Selkoe DJ. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 1999; 399:A23-A31. The amyloid story of Alzheimer's disease with all its might.
17. Yamada M, Sodeyama N, Itoh Y, Suematsu N, Otomo E, Matsushita M, Mizurawa H. Butyrylcholinesterase K variant and cerebral amyloid angiopathy. Stroke 1998; 29:2488-2490.
18. Singleton AB, Smith G, Gibson AM, Woodward R, Perry RH, Ince PG, et al. No association between the K variant of the butyrylcholinesterase gene and pathologically confirmed Alzheimer's disease. Hum Mol Genet 1998; 7:937-939.
19. van Dyck CH, Gelernter J, MacAvoy MG, Avery RA, Criden M, Okereke O, et al. Absence of an apolipoprotein E epsilon4 allele is associated with increased parietal regional cerebral blood flow asymmetry in Alzheimer disease. Arch Neurol 1998; 55:1460-1466.
20. Merchant C, Tang MX, Albert S, Manly J, Stern Y, Mayeux R. The influence of smoking on the risk of Alzheimer's disease. Neurology 1999; 52:1408-1412.
21. Oken BS, Storzbach DM, Kaye JA. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol 1998; 55:1409-1415. This is a thorough analysis of the solid facts behind a very popular over-the-counter drug.
22. Perry E, Walker M, Grace J, Perry R, Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci 1999; 22:273-280. This paper provides comprehensive coverage of the cognitive function of cholinergic mechanisms in the mammalian brain.
23. Senanayake N, Sanmuganathan PS. Extrapyramidal manifestations complicating organophosphorus insecticide poisoning. Hum Exp Toxicol 1995; 14:600-604.
24. Bhatt MH, Elias MA, Mankodi AK. Acute and reversible parkinsonism due to organophosphate pesticide intoxication: five cases. Neurology 1999; 52:1467-1471.
25. Kaufer D, Friedman A, Seidman S, Soreq S. Anticholinesterases induce multigenic transcriptional feedback response suppressing cholinergic neurotransmission. Chemico-Biol Interact 1999; 119-120:349-360.
26. Dally JJ, Greenfield SA. The release of acetylcholinesterase in vivo is regulated by dopaminergic systems in the guinea-pig substantia nigra. Neurochem Int 1994; 25:339-344.
27. Sternfeld M, Ming G, Song H, Sela K, Timburg R, Poo M, et al. Acetylcholinesterase enhances neurite growth and synapse development through alternative contributions of its hydrolytic capacity, core protein, and variable C termini. J Neurosci 1998; 18:1240-1249.
28. Grifman M, Galyam N, Seidman S, Soreq H. Functional redundancy of acetylcholinesterase and neuroligin in mammalian neuritogenesis. Proc Natl Acad Sci USA 1998; 95:13935-13940.
29. Grisaru D, Sternfeld M, Eldor A, Glick D, Soreq H. Structural roles of acetylcholinesterase variants in biology and pathology. Eur J Biochem 1999; 264:1-15.
30. Menegon A, Board PG, Blackburn AC, Mellick GD, Le Couteur DG. Parkinson's disease, pesticides, and glutathione transferase polymorphisms. Lancet 1998; 352:1344-1346. The triple mechanism enabling the connection between organophosphate anti-AChEs, the blood-brain barrier and genetic susceptibility to Parkinson's disease is depicted here in a very elegant way.
31. Kuhn W, Winkel R, Woitalla D, Meves S, Przuntek H, Muller T. High prevalence of parkinsonism after occupational exposure to lead-sulfate batteries. Neurology 1998; 50:1885-1886.
32. McGue M, Gottesman II. Genetic linkage in schizophrenia: perspectives from genetic epidemiology. Schizophr Bull 1989; 15:453-464.
33. Leonard S, Adams C, Breese CR, Adler LE, Bickford P, Byerley W, et al. Nicotinic receptor function in schizophrenia. Schizophr Bull 1996; 22:431-445.
34. Adler LE, Olincy A, Waldo M, Harris JG, Griffith J, Stevens K, et al. Schizophrenia, sensory gating, and nicotinic receptors. Schizophr Bull 1998; 24:189-202. Why did Joan d'Arc hear noises? This review integrates previous knowledge in the field, human studies and animal models into a molecular mechanism that could potentially explain this phenomenon in a most coherent way.
35. Griffith JM, O'Neill JE, Petty F, Garver D, Young D, Freedman R. Nicotinic receptor desensitization and sensory gating deficits in schizophrenia. Biol Psychiatry 1998; 44:98-106.
36. Friedman JI, Temporini H, Davis KL. Pharmacologic strategies for augment-ing cognitive performance in schizophrenia. Biol Psychiatry 1999; 45:1-16.
37. Feldman RG. Occupational and enviromental neurotoxicology. Philadelphia: Lippincott-Raven Publishers; 1999. This is a new comprehensive textbook in an important field with increasing significance to human health and well-being.
38. Bell IR, Schwartz GE, Amend D, Peterson JM, Stini WA. Sensitization to early life stress and response to chemical odors in older adults. Biol Psychiatry 1994; 35:857-863.
39. Kaufer D, Friedman A, Soreq H. The vicious circle: long-lasting transcriptional modulation of cholinergic neurotransmission following stress and anticholinesterase exposure. Neuroscientist 1999; 5:173-183.
40. Sorg BA, Prasad BM. Potential role of stress and sensitization in the development and expression of multiple chemical sensitivity. Environ Health Perspect 1997; 105 (Suppl 2):467-471. The complex, ill-defined MCS syndrome is discussed here at length.
41. Thomas JG. A critical analysis of multiple chemical sensitivities. Med Hypotheses 1998; 50:303-311.
42. Himuro K, Murayama S, Nishiyama K, Shinoe T, Iwase H, Nagao M, et al. Distal sensory axonopathy after sarin intoxication. Neurology 1998; 51:1195-1197. This is an important reminder of the delayed consequences of modern-time terrorism.
43. Nozaki H, Aikawa N, Shinozawa Y, Hori S, Fujishima S, Takuma K, et al. Sarin poisoning in Tokyo subway. Lancet 1995; 345:980-981.
44. +efflux and neuronal apoptosis. Science 1999; 284:336-339. This is an impressive paper, dealing with novel N-methyl-D-aspartate receptor-mediated effects.
45. Marrelli SP, Johnson TD, Khorovets A, Childres WF, Bryan RM Jr. Altered function of inward rectifier potassium channels in cerebrovascular smooth muscle after ischemia/reperfusion. Stroke 1998; 29:1469-1474.
46. Xie J, McCobb DP. Control of alternative splicing of potassium channels by stress hormones. Science 1998; 280:443-446. An interesting concept is presented that connects the effect of stress hormones with alternative splicing, and proves its physiological significance.
47. Yu SP, Farhangrazi ZS, Ying HS, Yeh CH, Choi DW. Enhancement of outward potassium current may participate in beta-amyloid peptide-induced cortical neuronal death. Neurobiol Dis 1998;5:81-88.
48. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz M, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1998; 95:8880-8885.
49. Gidday JM, Park TS, Shah AR, Gonzales ER. Modulation of basal and postischemic leukocyte-endothelial adherence by nitric oxide. Stroke 1998; 29:1423-1430.
50. Urushitani M, Shimohama S, Kihara T, Sawada H, Akaike A, Ibi M, et al. Mechanism of selective motor neuronal death after exposure of spinal cord to glutamate: involvement of glutamate-induced nitric oxide in motor neuron toxicity and nonmotor neuron protection. Ann Neurol 1998;44:796-807.
51. Clementi E, Brown GC, Foxwell N, Moncada S. On the mechanism by which vascular endothelial cells regulate their oxygen consumption. Proc Natl Acad Sci USA 1999; 96:1559-1562. This pioneering investigation opens new possibilities for unravelling the secrets of endothelial cells.
52. Hiramatsu M, Murai M, Kameyama T. Different modulation of cholinergic neuronal systems by dynorphin A (1-13) in carbon monoxide-exposed mice. Biochem Pharmacol 1999; 57:1321-1329.
53. Pema PJ, Horak HA, Wyatt RH. Myelopathy caused by nitrous oxide toxicity. AJNR Am J Neuroradiol 1998; 19:894-896.